{"transactions":[{"id":994424,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":39150,"kind":"person","name":"Knobil Katharine","position":1,"cik":"0001768011","reported_name":"Knobil Katharine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-19T21:18:31.000Z","date":"2025-11-17","kind":"grant","planned":false,"acquired":true,"shares":137330,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for service as a director for the year 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025."}],"balance_after":137330,"derivative":{"exercise_price":0.9548,"expiration_date":"2035-11-17","underlying":"Common Stock","underlying_shares":137330},"source":{"system":"sec-edgar","filing":"0001768011-25-000003","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000176801125000003/primary_doc.xml","form_type":"4"}},{"id":994423,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":39150,"kind":"person","name":"Knobil Katharine","position":1,"cik":"0001768011","reported_name":"Knobil Katharine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-19T21:18:31.000Z","date":"2025-11-17","kind":"grant","planned":false,"acquired":true,"shares":84411,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for the remaining options due as service as a director for the year 2024. 30,000 shares were previously granted on February 12, 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025."}],"balance_after":84411,"derivative":{"exercise_price":0.9548,"expiration_date":"2035-11-17","underlying":"Common Stock","underlying_shares":84411},"source":{"system":"sec-edgar","filing":"0001768011-25-000003","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000176801125000003/primary_doc.xml","form_type":"4"}},{"id":994422,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-19T21:10:21.000Z","date":"2025-11-17","kind":"grant","planned":false,"acquired":true,"shares":137330,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for service as a director for the year 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025."}],"balance_after":137330,"derivative":{"exercise_price":0.9548,"expiration_date":"2035-11-17","underlying":"Common Stock","underlying_shares":137330},"source":{"system":"sec-edgar","filing":"0001270905-25-000003","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000127090525000003/primary_doc.xml","form_type":"4"}},{"id":994421,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-19T21:10:21.000Z","date":"2025-11-17","kind":"grant","planned":false,"acquired":true,"shares":84411,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for the remaining options due as service as a director for the year 2024. 30,000 shares were previously granted on February 12, 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025."}],"balance_after":84411,"derivative":{"exercise_price":0.9548,"expiration_date":"2035-11-17","underlying":"Common Stock","underlying_shares":84411},"source":{"system":"sec-edgar","filing":"0001270905-25-000003","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000127090525000003/primary_doc.xml","form_type":"4"}},{"id":994420,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-19T21:01:15.000Z","date":"2025-11-17","kind":"grant","planned":false,"acquired":true,"shares":137330,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for service as a director for the year 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for service as a director for the year 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025."}],"balance_after":137330,"derivative":{"exercise_price":0.9548,"expiration_date":"2035-11-17","underlying":"Common Stock","underlying_shares":137330},"source":{"system":"sec-edgar","filing":"0001104659-25-114081","document":"tm2531774-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465925114081/tm2531774-1_4seq1.xml","form_type":"4"}},{"id":994419,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-19T21:01:15.000Z","date":"2025-11-17","kind":"grant","planned":false,"acquired":true,"shares":84411,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for the remaining options due as service as a director for the year 2024. 30,000 shares were previously granted on February 12, 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for the remaining options due as service as a director for the year 2024. 30,000 shares were previously granted on February 12, 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025."}],"balance_after":84411,"derivative":{"exercise_price":0.9548,"expiration_date":"2035-11-17","underlying":"Common Stock","underlying_shares":84411},"source":{"system":"sec-edgar","filing":"0001104659-25-114081","document":"tm2531774-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465925114081/tm2531774-1_4seq1.xml","form_type":"4"}},{"id":1008729,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":73641,"kind":"person","name":"Corzo Kathryn Penkus","position":1,"cik":"0001884123","reported_name":"Corzo Kathryn Penkus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-04T22:09:13.000Z","date":"2025-10-31","kind":"grant","planned":false,"acquired":true,"shares":147611,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. The shares vest equally over thirty six (36) monthly installments, subject to the Reporting Person's continued service as a director. The option exercise price is the closing price on the date of the grant, October 31, 2025."}],"balance_after":147611,"derivative":{"exercise_price":0.9877,"expiration_date":"2035-10-31","underlying":"Common Stock","underlying_shares":147611},"source":{"system":"sec-edgar","filing":"0001884123-25-000010","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000188412325000010/primary_doc.xml","form_type":"4"}},{"id":1008727,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-11-04T22:03:27.000Z","date":"2025-10-31","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One fourth of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second, third and fourth anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, October 31, 2025."}],"balance_after":250000,"derivative":{"exercise_price":0.9877,"expiration_date":"2035-10-31","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001755495-25-000003","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000175549525000003/primary_doc.xml","form_type":"4"}},{"id":1268100,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-02-14T22:20:34.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One third of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second and third anniversary of the grant date subject to the Reporting Person's continued service as a director. The option exercise price is the closing price on the date of the grant, February 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One third of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second and third anniversary of the grant date subject to the Reporting Person's continued service as a director. The option exercise price is the closing price on the date of the grant, February 12, 2025."}],"balance_after":30000,"derivative":{"exercise_price":1.59,"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-25-014321","document":"tm256716-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465925014321/tm256716-7_4seq1.xml","form_type":"4"}},{"id":1268099,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":39150,"kind":"person","name":"Knobil Katharine","position":1,"cik":"0001768011","reported_name":"Knobil Katharine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-02-14T22:19:38.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One third of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second and third anniversary of the grant date subject to the Reporting Person's continued service as a director. The option exercise price is the closing price on the date of the grant, February 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One third of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second and third anniversary of the grant date subject to the Reporting Person's continued service as a director. The option exercise price is the closing price on the date of the grant, February 12, 2025."}],"balance_after":30000,"derivative":{"exercise_price":1.59,"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-25-014318","document":"tm256716-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465925014318/tm256716-6_4seq1.xml","form_type":"4"}},{"id":1268098,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-02-14T22:18:35.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One third of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second and third anniversary of the grant date subject to the Reporting Person's continued service as a director. The option exercise price is the closing price on the date of the grant, February 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One third of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second and third anniversary of the grant date subject to the Reporting Person's continued service as a director. The option exercise price is the closing price on the date of the grant, February 12, 2025."}],"balance_after":30000,"derivative":{"exercise_price":1.59,"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-25-014317","document":"tm256716-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465925014317/tm256716-5_4seq1.xml","form_type":"4"}},{"id":1268097,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-02-14T22:17:32.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One third of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second and third anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, February 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One third of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second and third anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, February 12, 2025."}],"balance_after":50000,"derivative":{"exercise_price":1.59,"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-25-014315","document":"tm256716-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465925014315/tm256716-4_4seq1.xml","form_type":"4"}},{"id":1322178,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-26T21:01:17.000Z","date":"2024-12-23","kind":"purchase","planned":false,"acquired":true,"shares":11085,"price":3.2,"value":35472.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Acquired from the Issuer on December 23, 2024 pursuant to a Securities Purchase Agreement dated December 19, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On January 26, 2023, the Issuer effected a 1-for-10 reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Acquired from the Issuer on December 23, 2024 pursuant to a Securities Purchase Agreement dated December 19, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The reportable securities are directly owned by Aisling Capital IV, LP (\"Aisling\"), and which may be deemed to be beneficially owned by Aisling Capital Partners IV, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners IV LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the \"Managers\") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms, who have shared voting and dispositive power over the shares. Mr. Elms, the Reporting Person, disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, and the inclusion of these securities herein shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reportable securities are directly owned by Aisling Capital IV, LP (\"Aisling\"), and which may be deemed to be beneficially owned by Aisling Capital Partners IV, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners IV LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the \"Managers\") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms, who have shared voting and dispositive power over the shares. Mr. Elms, the Reporting Person, disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, and the inclusion of these securities herein shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purpose."}],"balance_after":325370,"source":{"system":"sec-edgar","filing":"0001104659-24-131704","document":"tm2432058-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465924131704/tm2432058-1_4seq1.xml","form_type":"4"}},{"id":1323293,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":66498,"kind":"organization","name":"New Enterprise Associates 16, L.P.","position":1,"cik":"0001694560","reported_name":"New Enterprise Associates 16, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":66499,"kind":"organization","name":"NEA Partners 16, L.P.","position":2,"cik":"0001712881","reported_name":"NEA Partners 16, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":66500,"kind":"organization","name":"NEA 16 GP, LLC","position":3,"cik":"0001712882","reported_name":"NEA 16 GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61210,"kind":"person","name":"BASKETT FOREST","position":4,"cik":"0001277631","reported_name":"BASKETT FOREST","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38171,"kind":"person","name":"Chang Carmen","position":5,"cik":"0001746342","reported_name":"Chang Carmen","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":31983,"kind":"person","name":"Behbahani Ali","position":6,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23293,"kind":"person","name":"Florence Anthony A. Jr.","position":7,"cik":"0001559827","reported_name":"Florence Anthony A. Jr.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23295,"kind":"person","name":"Makhzoumi Mohamad","position":8,"cik":"0001630226","reported_name":"Makhzoumi Mohamad","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23294,"kind":"person","name":"SANDELL SCOTT D","position":9,"cik":"0001237289","reported_name":"SANDELL SCOTT D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61190,"kind":"person","name":"Walker Paul Edward","position":10,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-23T21:40:48.000Z","date":"2024-12-23","kind":"purchase","planned":false,"acquired":true,"shares":554250,"price":3.2,"value":1773600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on December 23, 2024 pursuant to a Securities Purchase Agreement dated December 19, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On January 26, 2023, the Issuer effected a 1-for-10 reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities are directly held by New Enterprise Associates 16, L.P. (\"NEA 16\"), and indirectly held by NEA Partners 16, L.P. (\"NEA Partners 16\"), the sole general partner of NEA 16, NEA 16 GP, LLC (\"NEA 16 GP\"), the sole general partner of NEA Partners 16, and the individual managers of NEA 16 GP (NEA Partners 16, NEA 16 GP and the individual managers of NEA 16 GP, together, the \"Indirect Reporting Persons\").The individual managers of NEA 16 GP are Forest Baskett, Ali Behbahani, Carmen Chang, Anthony A. Florence, Jr., Mohamad Makhzoumi,  Scott D. Sandell, and Paul Walker. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares of the Issuer held by NEA 16 in which the Indirect Reporting Persons have no pecuniary interest."}],"balance_after":1625678,"source":{"system":"sec-edgar","filing":"0000950170-24-139630","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000095017024139630/ownership.xml","form_type":"4"}},{"id":1862924,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-09T01:35:39.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vests on June 6, 2024, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":8000,"derivative":{"exercise_price":1.72,"expiration_date":"2033-06-05","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-23-035617","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919123035617/doc4.xml","form_type":"4"}},{"id":1862923,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T01:35:39.000Z","date":"2021-03-25","kind":"gift","planned":false,"acquired":true,"shares":7142,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By the Scott Eansor 2020 Exempt Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 10-1 reverse stock split which became effective on January 16, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a 10-1 reverse stock split which became effective on January 16, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person transferred these shares to a trust of which the Reporting Person is the trustee. The Reporting Person's immediate family is the sole beneficiary of the trust."}],"balance_after":7142,"source":{"system":"sec-edgar","filing":"0001209191-23-035617","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919123035617/doc4.xml","form_type":"4"}},{"id":1862922,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T01:35:39.000Z","date":"2021-03-25","kind":"gift","planned":false,"acquired":true,"shares":7142,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By the John R. Eansor 2020 Exempt Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 10-1 reverse stock split which became effective on January 16, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a 10-1 reverse stock split which became effective on January 16, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person transferred these shares to a trust of which the Reporting Person is the trustee. The Reporting Person's immediate family is the sole beneficiary of the trust."}],"balance_after":7142,"source":{"system":"sec-edgar","filing":"0001209191-23-035617","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919123035617/doc4.xml","form_type":"4"}},{"id":1862921,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T01:35:39.000Z","date":"2021-03-25","kind":"gift","planned":false,"acquired":false,"shares":14285,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 10-1 reverse stock split which became effective on January 16, 2023."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Reporting Person transferred these shares to a trust of which the Reporting Person is the trustee. The Reporting Person's immediate family is the sole beneficiary of the trust."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a 10-1 reverse stock split which became effective on January 16, 2023."}],"balance_after":2428,"source":{"system":"sec-edgar","filing":"0001209191-23-035617","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919123035617/doc4.xml","form_type":"4"}},{"id":1862920,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T01:35:39.000Z","date":"2021-03-16","kind":"purchase","planned":false,"acquired":true,"shares":14285,"price":17.5,"value":249987.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 10-1 reverse stock split which became effective on January 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects a 10-1 reverse stock split which became effective on January 16, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a 10-1 reverse stock split which became effective on January 16, 2023."}],"balance_after":16713,"source":{"system":"sec-edgar","filing":"0001209191-23-035617","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919123035617/doc4.xml","form_type":"4"}},{"id":1862919,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":39150,"kind":"person","name":"Knobil Katharine","position":1,"cik":"0001768011","reported_name":"Knobil Katharine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-09T01:34:35.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests on June 6, 2024, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":8000,"derivative":{"exercise_price":1.72,"expiration_date":"2033-06-05","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-23-035616","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919123035616/doc4.xml","form_type":"4"}},{"id":1862918,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-09T01:33:44.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests on June 6, 2024, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":8000,"derivative":{"exercise_price":1.72,"expiration_date":"2033-06-05","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-23-035615","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919123035615/doc4.xml","form_type":"4"}},{"id":1862917,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-09T01:32:52.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests on June 6, 2024, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":8000,"derivative":{"exercise_price":1.72,"expiration_date":"2033-06-05","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-23-035614","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919123035614/doc4.xml","form_type":"4"}},{"id":1897162,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-05-11T22:10:29.000Z","date":"2023-05-10","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal annual installments on May 10, 2024, May 10, 2025, May 10, 2026 and May 10, 2027 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":100000,"derivative":{"exercise_price":1.42,"expiration_date":"2033-05-10","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-23-028846","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919123028846/doc4.xml","form_type":"4"}},{"id":1984658,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":116265,"kind":"person","name":"Hoang Tsvetelina P","position":1,"cik":"0001763023","reported_name":"Hoang Tsvetelina P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Research and Development"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-01T21:52:28.000Z","date":"2023-02-27","kind":"grant","acquired":true,"shares":33159,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four year period commencing on March 27, 2023 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":33159,"derivative":{"exercise_price":2.14,"expiration_date":"2033-02-27","underlying":"Common Stock","underlying_shares":33159},"source":{"system":"sec-edgar","filing":"0001209191-23-014168","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919123014168/doc4.xml","form_type":"4"}},{"id":1984657,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":116264,"kind":"person","name":"Koneru Mythili","position":1,"cik":"0001776659","reported_name":"Koneru Mythili","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-01T21:51:32.000Z","date":"2023-02-27","kind":"grant","acquired":true,"shares":51918,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four year period commencing on March 27, 2023 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":51918,"derivative":{"exercise_price":2.14,"expiration_date":"2033-02-27","underlying":"Common Stock","underlying_shares":51918},"source":{"system":"sec-edgar","filing":"0001209191-23-014165","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919123014165/doc4.xml","form_type":"4"}},{"id":1984656,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":116263,"kind":"person","name":"Loiacono Michael","position":1,"cik":"0001679119","reported_name":"Loiacono Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-01T21:50:29.000Z","date":"2023-02-27","kind":"grant","acquired":true,"shares":38480,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four year period commencing on March 27, 2023 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":38480,"derivative":{"exercise_price":2.14,"expiration_date":"2033-02-27","underlying":"Common Stock","underlying_shares":38480},"source":{"system":"sec-edgar","filing":"0001209191-23-014161","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919123014161/doc4.xml","form_type":"4"}},{"id":1984655,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer & COO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-01T21:49:34.000Z","date":"2023-02-27","kind":"grant","acquired":true,"shares":46487,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four year period commencing on March 27, 2023 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":46487,"derivative":{"exercise_price":2.14,"expiration_date":"2033-02-27","underlying":"Common Stock","underlying_shares":46487},"source":{"system":"sec-edgar","filing":"0001209191-23-014158","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919123014158/doc4.xml","form_type":"4"}},{"id":1984654,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":116262,"kind":"person","name":"Agopyan Nadia","position":1,"cik":"0001784758","reported_name":"Agopyan Nadia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Regulatory Affairs"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-01T21:47:45.000Z","date":"2023-02-27","kind":"grant","acquired":true,"shares":34154,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four year period commencing on March 27, 2023 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":34154,"derivative":{"exercise_price":2.14,"expiration_date":"2033-02-27","underlying":"Common Stock","underlying_shares":34154},"source":{"system":"sec-edgar","filing":"0001209191-23-014155","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919123014155/doc4.xml","form_type":"4"}},{"id":1984910,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":116268,"kind":"person","name":"Szymanska Anna","position":1,"cik":"0001804499","reported_name":"Szymanska Anna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President, Quality"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-01T16:48:42.000Z","date":"2023-02-27","kind":"grant","acquired":true,"shares":29947,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four year period commencing on March 27, 2023 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":29947,"derivative":{"exercise_price":2.14,"expiration_date":"2033-02-27","underlying":"Common Stock","underlying_shares":29947},"source":{"system":"sec-edgar","filing":"0001209191-23-014157","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1804499/000120919123014157/doc4.xml","form_type":"4"}},{"id":2255700,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-26T20:12:40.000Z","date":"2022-05-24","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests on May 24, 2023, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":80000,"derivative":{"exercise_price":0.3377,"expiration_date":"2032-05-23","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001209191-22-032180","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919122032180/doc4.xml","form_type":"4"}},{"id":2255699,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":126886,"kind":"person","name":"Laskow-Pooley David","position":1,"cik":"0001638533","reported_name":"Laskow-Pooley David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-26T20:10:53.000Z","date":"2022-05-24","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests on May 24, 2023, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":80000,"derivative":{"exercise_price":0.3377,"expiration_date":"2032-05-23","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001209191-22-032175","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919122032175/doc4.xml","form_type":"4"}},{"id":2255698,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":39150,"kind":"person","name":"Knobil Katharine","position":1,"cik":"0001768011","reported_name":"Knobil Katharine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-26T20:10:00.000Z","date":"2022-05-24","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests on May 24, 2023, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":80000,"derivative":{"exercise_price":0.3377,"expiration_date":"2032-05-23","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001209191-22-032172","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919122032172/doc4.xml","form_type":"4"}},{"id":2255696,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-26T20:09:24.000Z","date":"2022-05-24","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests on May 24, 2023, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":80000,"derivative":{"exercise_price":0.3377,"expiration_date":"2032-05-23","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001209191-22-032169","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919122032169/doc4.xml","form_type":"4"}},{"id":2255697,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-26T20:08:18.000Z","date":"2022-05-24","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests on May 24, 2023, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":80000,"derivative":{"exercise_price":0.3377,"expiration_date":"2032-05-23","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001209191-22-032166","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919122032166/doc4.xml","form_type":"4"}},{"id":2316976,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":128751,"kind":"person","name":"Hoang Peter L.","position":1,"cik":"0001626893","reported_name":"Hoang Peter L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-03-29T01:06:03.000Z","date":"2022-03-24","kind":"tax_withholding","acquired":false,"shares":48376,"price":0.4848,"value":23452.6848,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to satisfy tax obligations with respect to the vesting of the RSUs."}],"balance_after":483286,"source":{"system":"sec-edgar","filing":"0001209191-22-021396","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919122021396/doc4.xml","form_type":"4"}},{"id":2316975,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":128751,"kind":"person","name":"Hoang Peter L.","position":1,"cik":"0001626893","reported_name":"Hoang Peter L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-03-29T01:06:03.000Z","date":"2022-03-24","kind":"grant","acquired":true,"shares":199094,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award."}],"balance_after":531662,"source":{"system":"sec-edgar","filing":"0001209191-22-021396","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919122021396/doc4.xml","form_type":"4"}},{"id":2316978,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer & COO"}}],"security":"Common Stock","published_at":"2022-03-29T01:04:44.000Z","date":"2022-03-24","kind":"tax_withholding","acquired":false,"shares":33465,"price":0.4848,"value":16223.832,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to satisfy tax obligations with respect to the vesting of the RSUs."}],"balance_after":2671845,"source":{"system":"sec-edgar","filing":"0001209191-22-021395","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919122021395/doc4.xml","form_type":"4"}},{"id":2316977,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer & COO"}}],"security":"Common Stock","published_at":"2022-03-29T01:04:44.000Z","date":"2022-03-24","kind":"grant","acquired":true,"shares":140823,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award."}],"balance_after":2705310,"source":{"system":"sec-edgar","filing":"0001209191-22-021395","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919122021395/doc4.xml","form_type":"4"}},{"id":2316974,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":128750,"kind":"person","name":"Kim Anthony H.","position":1,"cik":"0001759782","reported_name":"Kim Anthony H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-29T01:03:28.000Z","date":"2022-03-24","kind":"tax_withholding","acquired":false,"shares":36076,"price":0.4848,"value":17489.6448,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to satisfy tax obligations with respect to the vesting of the RSUs."}],"balance_after":114436,"source":{"system":"sec-edgar","filing":"0001209191-22-021394","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919122021394/doc4.xml","form_type":"4"}},{"id":2316973,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":128750,"kind":"person","name":"Kim Anthony H.","position":1,"cik":"0001759782","reported_name":"Kim Anthony H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-29T01:03:28.000Z","date":"2022-03-24","kind":"grant","acquired":true,"shares":150512,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award."}],"balance_after":150512,"source":{"system":"sec-edgar","filing":"0001209191-22-021394","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919122021394/doc4.xml","form_type":"4"}},{"id":2383027,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":128751,"kind":"person","name":"Hoang Peter L.","position":1,"cik":"0001626893","reported_name":"Hoang Peter L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-22T22:14:03.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":430000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":430000,"derivative":{"exercise_price":0.46,"expiration_date":"2032-02-17","underlying":"Common Stock","underlying_shares":430000},"source":{"system":"sec-edgar","filing":"0001209191-22-011791","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919122011791/doc4.xml","form_type":"4"}},{"id":2383026,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer & COO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-22T22:12:05.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":160000,"derivative":{"exercise_price":0.46,"expiration_date":"2032-02-17","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001209191-22-011787","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919122011787/doc4.xml","form_type":"4"}},{"id":2383025,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":116263,"kind":"person","name":"Loiacono Michael","position":1,"cik":"0001679119","reported_name":"Loiacono Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-22T22:09:06.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":140000,"derivative":{"exercise_price":0.46,"expiration_date":"2032-02-17","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001209191-22-011782","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919122011782/doc4.xml","form_type":"4"}},{"id":2383024,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":116264,"kind":"person","name":"Koneru Mythili","position":1,"cik":"0001776659","reported_name":"Koneru Mythili","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-22T22:07:43.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":160000,"derivative":{"exercise_price":0.46,"expiration_date":"2032-02-17","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001209191-22-011779","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919122011779/doc4.xml","form_type":"4"}},{"id":2383023,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":128750,"kind":"person","name":"Kim Anthony H.","position":1,"cik":"0001759782","reported_name":"Kim Anthony H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-22T22:06:27.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":160000,"derivative":{"exercise_price":0.46,"expiration_date":"2032-02-17","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001209191-22-011776","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919122011776/doc4.xml","form_type":"4"}},{"id":2383022,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":116265,"kind":"person","name":"Hoang Tsvetelina P","position":1,"cik":"0001763023","reported_name":"Hoang Tsvetelina P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Research and Development"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-22T22:04:56.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":40000,"derivative":{"exercise_price":0.46,"expiration_date":"2032-02-17","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-22-011769","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919122011769/doc4.xml","form_type":"4"}},{"id":2383021,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":116262,"kind":"person","name":"Agopyan Nadia","position":1,"cik":"0001784758","reported_name":"Agopyan Nadia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Regulatory Affairs"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-22T22:01:21.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":40000,"derivative":{"exercise_price":0.46,"expiration_date":"2032-02-17","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-22-011745","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919122011745/doc4.xml","form_type":"4"}},{"id":2383387,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":116268,"kind":"person","name":"Szymanska Anna","position":1,"cik":"0001804499","reported_name":"Szymanska Anna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President, Quality"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-22T17:10:57.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":40000,"derivative":{"exercise_price":0.46,"expiration_date":"2032-02-17","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-22-011786","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1804499/000120919122011786/doc4.xml","form_type":"4"}},{"id":2383388,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":130160,"kind":"person","name":"Garrett Gerald","position":1,"cik":"0001804510","reported_name":"Garrett Gerald","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President, Clinical Ops."}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-22T17:02:51.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":40000,"derivative":{"exercise_price":0.46,"expiration_date":"2032-02-17","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-22-011761","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1804510/000120919122011761/doc4.xml","form_type":"4"}},{"id":2479516,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":39150,"kind":"person","name":"Knobil Katharine","position":1,"cik":"0001768011","reported_name":"Knobil Katharine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-09T22:20:48.000Z","date":"2021-12-08","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a three-year period commencing on January 8, 2022, subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":125000,"derivative":{"exercise_price":1.2,"expiration_date":"2031-12-07","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-21-068837","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121068837/doc4.xml","form_type":"4"}},{"id":2674439,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":74711,"kind":"person","name":"Wasserman Frederick Gerald","position":1,"cik":"0001384383","reported_name":"Wasserman Frederick Gerald","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T22:57:40.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":12658,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the Company's 2020 Equity Incentive Plan and based on the closing price of $3.16 per share, on the day immediately preceding the date of the Company's 2021 annual meeting."}],"balance_after":65223,"source":{"system":"sec-edgar","filing":"0001209191-21-039635","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121039635/doc4.xml","form_type":"4"}},{"id":2674438,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":126886,"kind":"person","name":"Laskow-Pooley David","position":1,"cik":"0001638533","reported_name":"Laskow-Pooley David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T22:56:43.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":12658,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the Company's 2020 Equity Incentive Plan and based on the closing price of $3.16 per share, on the day immediately preceding the date of the Company's 2021 annual meeting."}],"balance_after":55223,"source":{"system":"sec-edgar","filing":"0001209191-21-039634","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121039634/doc4.xml","form_type":"4"}},{"id":2674437,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T22:55:04.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":12658,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the Company's 2020 Equity Incentive Plan and based on the closing price of $3.16 per share, on the day immediately preceding the date of the Company's 2021 annual meeting."}],"balance_after":29680,"source":{"system":"sec-edgar","filing":"0001209191-21-039632","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121039632/doc4.xml","form_type":"4"}},{"id":2674436,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T22:54:11.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":12658,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the Company's 2020 Equity Incentive Plan and based on the closing price of $3.16 per share, on the day immediately preceding the date of the Company's 2021 annual meeting."}],"balance_after":36940,"source":{"system":"sec-edgar","filing":"0001209191-21-039631","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121039631/doc4.xml","form_type":"4"}},{"id":2674435,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T22:53:11.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":12658,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the Company's 2020 Equity Incentive Plan and based on the closing price of $3.16 per share, on the day immediately preceding the date of the Company's 2021 annual meeting."}],"balance_after":7812008,"source":{"system":"sec-edgar","filing":"0001209191-21-039629","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121039629/doc4.xml","form_type":"4"}},{"id":2703826,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":74711,"kind":"person","name":"Wasserman Frederick Gerald","position":1,"cik":"0001384383","reported_name":"Wasserman Frederick Gerald","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-20T20:32:52.000Z","date":"2021-05-18","kind":"purchase","acquired":true,"shares":10000,"price":2.4098,"value":24098.0,"ownership":{"direct":true},"balance_after":52565,"source":{"system":"sec-edgar","filing":"0001209191-21-034427","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121034427/doc4.xml","form_type":"4"}},{"id":2779890,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-18T21:18:33.000Z","date":"2021-03-16","kind":"purchase","acquired":true,"shares":5714285,"price":1.75,"value":9999998.75,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":10714285,"source":{"system":"sec-edgar","filing":"0001209191-21-021818","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121021818/doc4.xml","form_type":"4"}},{"id":2779889,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":120990,"kind":"person","name":"Sonsini Peter W.","position":1,"cik":"0001559807","reported_name":"Sonsini Peter W.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-18T21:17:55.000Z","date":"2021-03-16","kind":"purchase","acquired":true,"shares":5714285,"price":1.75,"value":9999998.75,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":10714285,"source":{"system":"sec-edgar","filing":"0001209191-21-021817","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121021817/doc4.xml","form_type":"4"}},{"id":2779888,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":23294,"kind":"person","name":"SANDELL SCOTT D","position":1,"cik":"0001237289","reported_name":"SANDELL SCOTT D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-18T21:17:11.000Z","date":"2021-03-16","kind":"purchase","acquired":true,"shares":5714285,"price":1.75,"value":9999998.75,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":10714285,"source":{"system":"sec-edgar","filing":"0001209191-21-021816","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121021816/doc4.xml","form_type":"4"}},{"id":2779887,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":123060,"kind":"person","name":"MAKOWER JOSHUA","position":1,"cik":"0001235952","reported_name":"MAKOWER JOSHUA","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-18T21:16:26.000Z","date":"2021-03-16","kind":"purchase","acquired":true,"shares":5714285,"price":1.75,"value":9999998.75,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":10714285,"source":{"system":"sec-edgar","filing":"0001209191-21-021815","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121021815/doc4.xml","form_type":"4"}},{"id":2779885,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":23295,"kind":"person","name":"Makhzoumi Mohamad","position":1,"cik":"0001630226","reported_name":"Makhzoumi Mohamad","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-18T21:15:24.000Z","date":"2021-03-16","kind":"purchase","acquired":true,"shares":5714285,"price":1.75,"value":9999998.75,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":10714285,"source":{"system":"sec-edgar","filing":"0001209191-21-021814","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121021814/doc4.xml","form_type":"4"}},{"id":2779886,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":23293,"kind":"person","name":"Florence Anthony A. Jr.","position":1,"cik":"0001559827","reported_name":"Florence Anthony A. Jr.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-18T21:14:03.000Z","date":"2021-03-16","kind":"purchase","acquired":true,"shares":5714285,"price":1.75,"value":9999998.75,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":10714285,"source":{"system":"sec-edgar","filing":"0001209191-21-021813","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121021813/doc4.xml","form_type":"4"}},{"id":2779884,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":38171,"kind":"person","name":"Chang Carmen","position":1,"cik":"0001746342","reported_name":"Chang Carmen","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-18T21:12:44.000Z","date":"2021-03-16","kind":"purchase","acquired":true,"shares":5714285,"price":1.75,"value":9999998.75,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":10714285,"source":{"system":"sec-edgar","filing":"0001209191-21-021812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121021812/doc4.xml","form_type":"4"}},{"id":2779882,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-18T21:11:40.000Z","date":"2021-03-16","kind":"purchase","acquired":true,"shares":5714285,"price":1.75,"value":9999998.75,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":10714285,"source":{"system":"sec-edgar","filing":"0001209191-21-021811","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121021811/doc4.xml","form_type":"4"}},{"id":2779883,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":61210,"kind":"person","name":"BASKETT FOREST","position":1,"cik":"0001277631","reported_name":"BASKETT FOREST","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-18T21:09:53.000Z","date":"2021-03-16","kind":"purchase","acquired":true,"shares":5714285,"price":1.75,"value":9999998.75,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":10714285,"source":{"system":"sec-edgar","filing":"0001209191-21-021810","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121021810/doc4.xml","form_type":"4"}},{"id":2779881,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":66498,"kind":"organization","name":"New Enterprise Associates 16, L.P.","position":1,"cik":"0001694560","reported_name":"New Enterprise Associates 16, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":66499,"kind":"organization","name":"NEA Partners 16, L.P.","position":2,"cik":"0001712881","reported_name":"NEA Partners 16, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":66500,"kind":"organization","name":"NEA 16 GP, LLC","position":3,"cik":"0001712882","reported_name":"NEA 16 GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-18T21:08:23.000Z","date":"2021-03-16","kind":"purchase","acquired":true,"shares":5714285,"price":1.75,"value":9999998.75,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The shares are directly held by New Enterprise Associates 16, L.P. (\"NEA 16\"), and indirectly held by NEA Partners 16, L.P. (\"NEA Partners\"), the sole general partner of NEA 16, NEA 16 GP, LLC (\"NEA 16 GP\"), the sole general partner of NEA Partners 16, and the individual managers of NEA 16 GP (NEA Partners 16, NEA 16 GP and the individual managers of NEA 16 GP, together, the \"Indirect Reporting Persons\").The individual managers of NEA 16 GP are Forest Baskett, Ali Behbahani, Carmen Chang, Anthony A. Florence, Jr., Mohamad Makhzoumi, Josh Makower, Scott D. Sandell, Peter W. Sonsini and Paul Walker. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares of the Issuer held by NEA 16 in which the Indirect Reporting Persons have no pecuniary interest."}],"balance_after":10714285,"source":{"system":"sec-edgar","filing":"0001209191-21-021809","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121021809/doc4.xml","form_type":"4"}},{"id":2779880,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-18T20:39:16.000Z","date":"2021-03-16","kind":"purchase","acquired":true,"shares":1714285,"price":1.75,"value":2999998.75,"ownership":{"direct":true},"balance_after":7799350,"source":{"system":"sec-edgar","filing":"0001209191-21-021775","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121021775/doc4.xml","form_type":"4"}},{"id":2779879,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2021-03-18T20:38:07.000Z","date":"2021-03-16","kind":"purchase","acquired":true,"shares":571428,"price":1.75,"value":999999.0,"ownership":{"direct":true},"balance_after":2564487,"source":{"system":"sec-edgar","filing":"0001209191-21-021773","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121021773/doc4.xml","form_type":"4"}},{"id":2779878,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":128751,"kind":"person","name":"Hoang Peter L.","position":1,"cik":"0001626893","reported_name":"Hoang Peter L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-03-18T20:36:47.000Z","date":"2021-03-16","kind":"purchase","acquired":true,"shares":142857,"price":1.75,"value":249999.75,"ownership":{"direct":true},"balance_after":332568,"source":{"system":"sec-edgar","filing":"0001209191-21-021771","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121021771/doc4.xml","form_type":"4"}},{"id":2779877,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-18T20:35:34.000Z","date":"2021-03-16","kind":"purchase","acquired":true,"shares":1142857,"price":1.75,"value":1999999.75,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reportable securities are directly owned by Aisling Capital IV, LP (\"Aisling\"), and which may be deemed to be beneficially owned by Aisling Capital Partners IV, LP (\"Aisling GP\"), as general partner of Aisling, Aisling Capital Partners IV LLC (\"Aisling Partners\"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the \"Managers\") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms, who have shared voting and dispositive power over the shares. Mr. Elms, the Reporting Person, disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, and the inclusion of these securities herein shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purpose."}],"balance_after":3142857,"source":{"system":"sec-edgar","filing":"0001209191-21-021769","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121021769/doc4.xml","form_type":"4"}},{"id":2864257,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-02-12T22:39:04.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four year period commencing on March 10, 2021 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":140000,"derivative":{"exercise_price":3.29,"expiration_date":"2031-02-10","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001209191-21-010312","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121010312/doc4.xml","form_type":"4"}},{"id":2864256,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":116263,"kind":"person","name":"Loiacono Michael","position":1,"cik":"0001679119","reported_name":"Loiacono Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-02-12T22:36:33.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four year period commencing on March 10, 2021 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":140000,"derivative":{"exercise_price":3.29,"expiration_date":"2031-02-10","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001209191-21-010302","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121010302/doc4.xml","form_type":"4"}},{"id":2864255,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":116264,"kind":"person","name":"Koneru Mythili","position":1,"cik":"0001776659","reported_name":"Koneru Mythili","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-02-12T22:34:59.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four year period commencing on March 10, 2021 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":140000,"derivative":{"exercise_price":3.29,"expiration_date":"2031-02-10","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001209191-21-010297","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121010297/doc4.xml","form_type":"4"}},{"id":2864254,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":128750,"kind":"person","name":"Kim Anthony H.","position":1,"cik":"0001759782","reported_name":"Kim Anthony H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-02-12T22:31:03.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four year period commencing on March 10, 2021 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":160000,"derivative":{"exercise_price":3.29,"expiration_date":"2031-02-10","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001209191-21-010285","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121010285/doc4.xml","form_type":"4"}},{"id":2864253,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":116265,"kind":"person","name":"Hoang Tsvetelina P","position":1,"cik":"0001763023","reported_name":"Hoang Tsvetelina P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Research and Development"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-02-12T22:29:52.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four year period commencing on March 10, 2021 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":40000,"derivative":{"exercise_price":3.29,"expiration_date":"2031-02-10","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-21-010278","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121010278/doc4.xml","form_type":"4"}},{"id":2864252,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":128751,"kind":"person","name":"Hoang Peter L.","position":1,"cik":"0001626893","reported_name":"Hoang Peter L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-02-12T22:26:11.000Z","date":"2021-02-11","kind":"grant","acquired":true,"shares":430000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four year period commencing on March 11, 2021 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":430000,"derivative":{"exercise_price":3.06,"expiration_date":"2031-02-11","underlying":"Common Stock","underlying_shares":430000},"source":{"system":"sec-edgar","filing":"0001209191-21-010267","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121010267/doc4.xml","form_type":"4"}},{"id":2864251,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":116262,"kind":"person","name":"Agopyan Nadia","position":1,"cik":"0001784758","reported_name":"Agopyan Nadia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Regulatory Affairs"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-02-12T22:21:42.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four year period commencing on March 10, 2021 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":40000,"derivative":{"exercise_price":3.29,"expiration_date":"2031-02-10","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-21-010256","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121010256/doc4.xml","form_type":"4"}},{"id":2864250,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":112587,"kind":"person","name":"Wilson John Robert","position":1,"cik":"0001755569","reported_name":"Wilson John Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-12T22:18:48.000Z","date":"2020-05-19","kind":"grant","acquired":true,"shares":17022,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the\nCompany's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $2.35 per share, on the day immediately\npreceding the date of the Company's 2019 annual meeting."}],"balance_after":6085065,"source":{"system":"sec-edgar","filing":"0001209191-21-010250","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121010250/doc5.xml","form_type":"5"}},{"id":2864249,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":74711,"kind":"person","name":"Wasserman Frederick Gerald","position":1,"cik":"0001384383","reported_name":"Wasserman Frederick Gerald","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-12T22:17:22.000Z","date":"2020-05-19","kind":"grant","acquired":true,"shares":17022,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the\nCompany's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $2.35 per share, on the day immediately\npreceding the date of the Company's 2019 annual meeting."}],"balance_after":42565,"source":{"system":"sec-edgar","filing":"0001209191-21-010241","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121010241/doc5.xml","form_type":"5"}},{"id":2864248,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":126886,"kind":"person","name":"Laskow-Pooley David","position":1,"cik":"0001638533","reported_name":"Laskow-Pooley David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-12T22:13:53.000Z","date":"2020-05-19","kind":"grant","acquired":true,"shares":17022,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the\nCompany's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $2.35 per share, on the day immediately\npreceding the date of the Company's 2019 annual meeting."}],"balance_after":42565,"source":{"system":"sec-edgar","filing":"0001209191-21-010231","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121010231/doc5.xml","form_type":"5"}},{"id":2864247,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":61997,"kind":"person","name":"ELMS STEVE","position":1,"cik":"0001250195","reported_name":"ELMS STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-12T22:12:23.000Z","date":"2020-05-19","kind":"grant","acquired":true,"shares":17022,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the\nCompany's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $2.35 per share, on the day immediately\npreceding the date of the Company's 2019 annual meeting."}],"balance_after":17022,"source":{"system":"sec-edgar","filing":"0001209191-21-010226","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121010226/doc5.xml","form_type":"5"}},{"id":2864246,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-12T22:11:45.000Z","date":"2020-05-19","kind":"grant","acquired":true,"shares":17022,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the\nCompany's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $2.35 per share, on the day immediately\npreceding the date of the Company's 2019 annual meeting."}],"balance_after":24282,"source":{"system":"sec-edgar","filing":"0001209191-21-010224","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121010224/doc5.xml","form_type":"5"}},{"id":2864518,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":116268,"kind":"person","name":"Szymanska Anna","position":1,"cik":"0001804499","reported_name":"Szymanska Anna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President, Quality"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-02-12T17:37:26.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four year period commencing on March 10, 2021 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":40000,"derivative":{"exercise_price":3.29,"expiration_date":"2031-02-10","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-21-010306","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1804499/000120919121010306/doc4.xml","form_type":"4"}},{"id":2864517,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":130160,"kind":"person","name":"Garrett Gerald","position":1,"cik":"0001804510","reported_name":"Garrett Gerald","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President, Clinical Ops."}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-02-12T17:23:29.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in equal monthly installments over a four year period commencing on March 10, 2021 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":40000,"derivative":{"exercise_price":3.29,"expiration_date":"2031-02-10","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-21-010262","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1804510/000120919121010262/doc4.xml","form_type":"4"}},{"id":3104640,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":145378,"kind":"organization","name":"Eastern Capital LTD","position":1,"cik":"0001408408","reported_name":"Eastern Capital LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145379,"kind":"organization","name":"Portfolio Services Ltd.","position":2,"cik":"0001488856","reported_name":"Portfolio Services Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21577,"kind":"person","name":"DART KENNETH BRYAN","position":3,"cik":"0001331271","reported_name":"DART KENNETH BRYAN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E-1 Warrant","published_at":"2020-06-19T11:49:25.000Z","date":"2020-06-16","kind":"other","acquired":false,"shares":416667,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Series E-1 Warrant to purchase 416,667 shares of Common Stock of the Issuer at the exercise price of $15.00 per share with an expiration date of June 16, 2020, was not exercised by the Reporting Persons before such expiration."},{"field":"date","element":"transactionDate","label":"F1","text":"The Series E-1 Warrant to purchase 416,667 shares of Common Stock of the Issuer at the exercise price of $15.00 per share with an expiration date of June 16, 2020, was not exercised by the Reporting Persons before such expiration."},{"field":"shares","element":"transactionShares","label":"F1","text":"The Series E-1 Warrant to purchase 416,667 shares of Common Stock of the Issuer at the exercise price of $15.00 per share with an expiration date of June 16, 2020, was not exercised by the Reporting Persons before such expiration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series E-1 Warrant to purchase 416,667 shares of Common Stock of the Issuer at the exercise price of $15.00 per share with an expiration date of June 16, 2020, was not exercised by the Reporting Persons before such expiration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series E-1 Warrant to purchase 416,667 shares of Common Stock of the Issuer at the exercise price of $15.00 per share with an expiration date of June 16, 2020, was not exercised by the Reporting Persons before such expiration."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Series E-1 Warrant to purchase 416,667 shares of Common Stock of the Issuer at the exercise price of $15.00 per share with an expiration date of June 16, 2020, was not exercised by the Reporting Persons before such expiration."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Series E-1 Warrant to purchase 416,667 shares of Common Stock of the Issuer at the exercise price of $15.00 per share with an expiration date of June 16, 2020, was not exercised by the Reporting Persons before such expiration."}],"balance_after":0,"derivative":{"exercise_price":15,"exercise_date":"2015-03-09","expiration_date":"2020-06-16","underlying":"Common Stock","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0001408408-20-000029","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000140840820000029/ownership.xml","form_type":"4"}},{"id":3214046,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":128751,"kind":"person","name":"Hoang Peter L.","position":1,"cik":"0001626893","reported_name":"Hoang Peter L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-12T20:46:05.000Z","date":"2020-03-10","kind":"grant","acquired":true,"shares":388800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":388800,"derivative":{"exercise_price":2.12,"expiration_date":"2030-03-10","underlying":"Common Stock","underlying_shares":388800},"source":{"system":"sec-edgar","filing":"0001209191-20-018556","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919120018556/doc4.xml","form_type":"4"}},{"id":3214045,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":128751,"kind":"person","name":"Hoang Peter L.","position":1,"cik":"0001626893","reported_name":"Hoang Peter L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-12T20:46:05.000Z","date":"2020-03-10","kind":"grant","acquired":true,"shares":41200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents a bonus for 2019 performance granted under the Company's 2014 Omnibus Stock Ownership Plan. This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":41200,"derivative":{"exercise_price":2.12,"expiration_date":"2030-03-10","underlying":"Common Stock","underlying_shares":41200},"source":{"system":"sec-edgar","filing":"0001209191-20-018556","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919120018556/doc4.xml","form_type":"4"}},{"id":3214196,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-12T20:43:02.000Z","date":"2020-03-10","kind":"grant","acquired":true,"shares":113400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":113400,"derivative":{"exercise_price":2.12,"expiration_date":"2030-03-10","underlying":"Common Stock","underlying_shares":113400},"source":{"system":"sec-edgar","filing":"0001209191-20-018548","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919120018548/doc4.xml","form_type":"4"}},{"id":3214195,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":73642,"kind":"person","name":"Vera Juan","position":1,"cik":"0001755495","reported_name":"Vera Juan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-12T20:43:02.000Z","date":"2020-03-10","kind":"grant","acquired":true,"shares":26600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents a bonus for 2019 performance granted under the Company's 2014 Omnibus Stock Ownership Plan. This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":26600,"derivative":{"exercise_price":2.12,"expiration_date":"2030-03-10","underlying":"Common Stock","underlying_shares":26600},"source":{"system":"sec-edgar","filing":"0001209191-20-018548","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919120018548/doc4.xml","form_type":"4"}},{"id":3214044,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":116263,"kind":"person","name":"Loiacono Michael","position":1,"cik":"0001679119","reported_name":"Loiacono Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-12T20:40:57.000Z","date":"2020-03-10","kind":"grant","acquired":true,"shares":119100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":119100,"derivative":{"exercise_price":2.12,"expiration_date":"2030-03-10","underlying":"Common Stock","underlying_shares":119100},"source":{"system":"sec-edgar","filing":"0001209191-20-018539","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919120018539/doc4.xml","form_type":"4"}},{"id":3214043,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":116263,"kind":"person","name":"Loiacono Michael","position":1,"cik":"0001679119","reported_name":"Loiacono Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-12T20:40:57.000Z","date":"2020-03-10","kind":"grant","acquired":true,"shares":20900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents a bonus for 2019 performance granted under the Company's 2014 Omnibus Stock Ownership Plan. This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":20900,"derivative":{"exercise_price":2.12,"expiration_date":"2030-03-10","underlying":"Common Stock","underlying_shares":20900},"source":{"system":"sec-edgar","filing":"0001209191-20-018539","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919120018539/doc4.xml","form_type":"4"}},{"id":3214042,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":116264,"kind":"person","name":"Koneru Mythili","position":1,"cik":"0001776659","reported_name":"Koneru Mythili","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-12T20:40:01.000Z","date":"2020-03-10","kind":"grant","acquired":true,"shares":116100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":116100,"derivative":{"exercise_price":2.12,"expiration_date":"2030-03-10","underlying":"Common Stock","underlying_shares":116100},"source":{"system":"sec-edgar","filing":"0001209191-20-018535","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919120018535/doc4.xml","form_type":"4"}},{"id":3214041,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":116264,"kind":"person","name":"Koneru Mythili","position":1,"cik":"0001776659","reported_name":"Koneru Mythili","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-12T20:40:01.000Z","date":"2020-03-10","kind":"grant","acquired":true,"shares":23900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents a bonus for 2019 performance granted under the Company's 2014 Omnibus Stock Ownership Plan. This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":23900,"derivative":{"exercise_price":2.12,"expiration_date":"2030-03-10","underlying":"Common Stock","underlying_shares":23900},"source":{"system":"sec-edgar","filing":"0001209191-20-018535","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919120018535/doc4.xml","form_type":"4"}},{"id":3214040,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":128750,"kind":"person","name":"Kim Anthony H.","position":1,"cik":"0001759782","reported_name":"Kim Anthony H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-12T20:39:09.000Z","date":"2020-03-10","kind":"grant","acquired":true,"shares":127500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":127500,"derivative":{"exercise_price":2.12,"expiration_date":"2030-03-10","underlying":"Common Stock","underlying_shares":127500},"source":{"system":"sec-edgar","filing":"0001209191-20-018534","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919120018534/doc4.xml","form_type":"4"}},{"id":3214039,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":128750,"kind":"person","name":"Kim Anthony H.","position":1,"cik":"0001759782","reported_name":"Kim Anthony H.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-12T20:39:09.000Z","date":"2020-03-10","kind":"grant","acquired":true,"shares":32500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents a bonus for 2019 performance granted under the Company's 2014 Omnibus Stock Ownership Plan. This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":32500,"derivative":{"exercise_price":2.12,"expiration_date":"2030-03-10","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0001209191-20-018534","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919120018534/doc4.xml","form_type":"4"}},{"id":3214038,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":116265,"kind":"person","name":"Hoang Tsvetelina P","position":1,"cik":"0001763023","reported_name":"Hoang Tsvetelina P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Research and Development"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-12T20:38:04.000Z","date":"2020-03-10","kind":"grant","acquired":true,"shares":25400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":25400,"derivative":{"exercise_price":2.12,"expiration_date":"2030-03-10","underlying":"Common Stock","underlying_shares":25400},"source":{"system":"sec-edgar","filing":"0001209191-20-018531","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919120018531/doc4.xml","form_type":"4"}},{"id":3214037,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":116265,"kind":"person","name":"Hoang Tsvetelina P","position":1,"cik":"0001763023","reported_name":"Hoang Tsvetelina P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Research and Development"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-12T20:38:04.000Z","date":"2020-03-10","kind":"grant","acquired":true,"shares":14600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents a bonus for 2019 performance granted under the Company's 2014 Omnibus Stock Ownership Plan. This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":14600,"derivative":{"exercise_price":2.12,"expiration_date":"2030-03-10","underlying":"Common Stock","underlying_shares":14600},"source":{"system":"sec-edgar","filing":"0001209191-20-018531","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919120018531/doc4.xml","form_type":"4"}},{"id":3214036,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":116262,"kind":"person","name":"Agopyan Nadia","position":1,"cik":"0001784758","reported_name":"Agopyan Nadia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Regulatory Affairs"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-12T20:35:17.000Z","date":"2020-03-10","kind":"grant","acquired":true,"shares":32700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":32700,"derivative":{"exercise_price":2.12,"expiration_date":"2030-03-10","underlying":"Common Stock","underlying_shares":32700},"source":{"system":"sec-edgar","filing":"0001209191-20-018524","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919120018524/doc4.xml","form_type":"4"}},{"id":3214035,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":116262,"kind":"person","name":"Agopyan Nadia","position":1,"cik":"0001784758","reported_name":"Agopyan Nadia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Regulatory Affairs"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-12T20:35:17.000Z","date":"2020-03-10","kind":"grant","acquired":true,"shares":7300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents a bonus for 2019 performance granted under the Company's 2014 Omnibus Stock Ownership Plan. This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":7300,"derivative":{"exercise_price":2.12,"expiration_date":"2030-03-10","underlying":"Common Stock","underlying_shares":7300},"source":{"system":"sec-edgar","filing":"0001209191-20-018524","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919120018524/doc4.xml","form_type":"4"}},{"id":3214229,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":116268,"kind":"person","name":"Szymanska Anna","position":1,"cik":"0001804499","reported_name":"Szymanska Anna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President, Quality"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-12T16:41:58.000Z","date":"2020-03-10","kind":"grant","acquired":true,"shares":32500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date."}],"balance_after":32500,"derivative":{"exercise_price":2.12,"expiration_date":"2030-03-10","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0001209191-20-018543","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1804499/000120919120018543/doc4.xml","form_type":"4"}}],"next_cursor":"2020-03-12T16:41:58.000000Z,3214229"}